HCS main assets for pharmacology
Why have we decided to focus on cell imaging ?
1. Because this technology allows phenotypic screening to discover new compounds and new targets for complex diseases, such as neurodegenerative diseases and cancer.
On 1178 FDA-approved drugs & 3074 experimental drugs, there are only 394 targets. But the network and regulation of these targets are huge.
Furthermore, complex diseases with multi-cellular and multi-target implication need multi-target drugs.
2. Because cellular imagery is a muti-parametric assay which enables to follow several parameters within the same experiment.
Meet us at the first DYRK conference in Saint Malo, march 28th to April 1st | HCS-pharma · March 16, 2017 at 9:08 am
[…] Pharmacology […]